April 18, 2014 7:05 AM ET

Life Sciences Tools and Services

Company Overview of Hadasit Medical Research Services & Development Ltd.

Company Overview

Hadasit Medical Research Services & Development Ltd. promotes and commercializes its parent company’s intellectual property, and wealth of pre-clinical and clinical research and development capabilities through product licensing, establishing start-up companies, and collaboration with academy and industry. It promotes pre-clinical research services that are offered to biotechnology, pharmaceutical, and medical device industries. The company also handles the contractual aspects of various clinical trials. It promotes pre-clinical research services in the areas of cell biology, clinical diagnostics, consultations and counseling, disease models and experimental surgery, drug discovery, genetics...

Kiryat Hadassah

Jerusalem,  91120

Israel

Founded in 1986

Phone:

972 2 677 8757

Fax:

972 2 643 7712

Key Executives for Hadasit Medical Research Services & Development Ltd.

Chief Executive Officer
Vice President of Finance & Contracts
General Counsel
Vice President of Business Development
Executive Officer
Compensation as of Fiscal Year 2013.

Hadasit Medical Research Services & Development Ltd. Key Developments

BioLineRx Signs License Agreement with Yissum Research Development Company, B.G. Negev Technologies and Applications Ltd., and Hadasit Medical Research Services and Development Ltd

BioLineRx announced that it has signed a worldwide, exclusive license agreement with Yissum Research Development Company, B.G. Negev Technologies and Applications Ltd., and Hadasit Medical Research Services and Development Ltd. for BioLineRx to develop and commercialize BL-9020, for the treatment of Type 1 diabetes. Promising results of preclinical studies in a mouse model of Type 1 diabetes demonstrated that BL-9020 is able to inhibit the onset of diabetes. Previously, the project was developed under BioLineRx's Early Development Program as EDP-10. BL-9020 is a novel antibody treatment for prevention of the development of Type 1 diabetes. It was developed to treat Type 1 diabetes in early stage patients, during what is known as the 'honeymoon period'. At this early stage of the disease, the insulin-producing pancreatic cells are not completely destroyed and continue to secrete insulin. Pre-clinical studies suggest that BL-9020 can preserve surviving cells, thus preventing full maturation of the disease.

Hadasit and AstraZeneca PLC to Collaborate on Discovering and Developing Treatments for Cancer, Diabetes, and Respiratory Diseases

Hadasit and AstraZeneca plc will collaborate on discovering and developing treatments for cancer, diabetes, and respiratory diseases. The terms of the deal were not disclosed, but they probably include a small initial payment by AstraZeneca to Hadasit. Payments may increase if and when jointly discovered products move forward in AstraZeneca's pipeline. AstraZeneca will also be responsible for commercialization of products, if and when they reach market. Hadasit and Hadassah scientists will work in collaboration with teams from AstraZeneca's Innovative Medicines & Early Development organization for an initial period of three years.

Similar Private Companies By Industry

Company Name Region
Entera Bio Ltd. Middle East/Africa
Pluristem Ltd. Middle East/Africa
I2O Pharma Ltd. Middle East/Africa
RegeneEx Ltd. Middle East/Africa
AllergyFight Ltd. Middle East/Africa

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Hadasit Medical Research Services & Development Ltd., please visit www.hadasit.co.il. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.